Skip to main content
Contact us

Leading CDMO Companies in France

Your Trusted French Partners for Contract Manufacturing and Development

Applied Filters:Europe×Clear All
Showing 10 facilities
Cenexi
France

Cenexi

Cenexi

GMP plant on a four-hectare site is located 9 km east of Paris. It is a center of excellence for injectable ampoules.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), EDE (UAE), TGA (Australia)

COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)

USE: Human, Veterinary

BATCH SIZE: Large, Small, Medium

CONTROLLED SUBSTANCES: Lowest potential for abuse, Lower potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Low potential for abuse

THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (J) Antiinfectives for systemic use, (D) Dermatologicals, (P) Antiparasitic products, insecticides and repellents, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (C) Cardiovascular system, (A) Digestive tract and metabolism

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 10,000 µg/day)

REGION: Europe

AdhexPharma SAS
France

AdhexPharma SAS

AdhexPharma

CDMO for transdermal patches and oromucosal films.

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), MHRA (UK)

REGION: Europe

COMPLIANCE: FDA (cGMP), ISO, EMA (EU GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

SERVICES: Development services, Manufacturing services, Analytical / QC services

THERAPEUTIC AREAS OF EXPERTISE (ATC): (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (N) Nervous system

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Adragos Pharma | Maisons-Alfort
France

Adragos Pharma | Maisons-Alfort

Adragos Pharma

Specialised in prefilled syringes, liquid and lyophilised vials, it combines advanced aseptic filling, freeze-drying, and inspection systems.

THERAPEUTIC AREAS OF EXPERTISE (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (A) Digestive tract and metabolism

MARKETS: EMA (EU), NMPA (China), ANVISA (Brazil), Russian Health Authorities, SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities

REGION: Europe

BATCH SIZE: Large

USE: Human

BSL (Biological Safety Level): 1

SERVICES: Manufacturing services, Analytical / QC services, Regulatory services, Packaging

CONTROLLED SUBSTANCES: Lowest potential for abuse

COMPLIANCE: ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TITCK (Turkish Health Authorities), SFDA (Saudi Food & Drug Authority), NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 10,000 µg/day)

Adragos Pharma | Livron
France

Adragos Pharma | Livron

Adragos Pharma

Manufacture of sterile liquids and suppositories. We handle more than 100 molecules, narcotics management, and analysis and stability services.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), MHRA (UK), MFDS (South Korea), CDSCO (India), TGA (Australia)

SERVICES: Logistics, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

BATCH SIZE: Large, Small, Medium

USE: Human

COMPLIANCE: EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Cenexi SAS
France

Cenexi SAS

Cenexi

Accueil Sites Osny. Acquired in 2011, the Osny site specializes in the development and production of highly active solid pharmaceutical forms.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), ANVISA (Brazil), MHRA (UK), MFDS (South Korea)

REGION: Europe

COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)

USE: Human

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (G) Genito urinary system and sex hormones

BATCH SIZE: Small, Medium

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Cenexi Hérouville Saint Clair
France

Cenexi Hérouville Saint Clair

Cenexi

The Hérouville-Saint-Clair site, located near Caen, in Normandy, specializes in the manufacture and filling of injectable and non-injectable sterile liquids.

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), ANVISA (Brazil), Russian Health Authorities, MHRA (UK), MFDS (South Korea), TGA (Australia)

REGION: Europe

COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), NMPA (China GMP), EMA (EU GMP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

USE: Human

SERVICES: Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (N) Nervous system, (A) Digestive tract and metabolism

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

BATCH SIZE: Small, Medium

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Limited view

FDF / DRUG PRODUCTS manufacturing site

MAI network supplier

French CDMO key player in drug development and delivery of oral technologies serving the pharma and bio industries.

Location available after registration

Limited view

SERVICES manufacturing site

MAI network supplier

Make affordable healthcare solutions that improve and simplify patients lives.

Location available after registration

Limited view

FDF / DRUG PRODUCTS manufacturing site

MAI network supplier

CDM Lavoisier is specialized in the manufacturing of glass ampoules, glass vials and plastic (BFS) ampoules.

Location available after registration

Suggested Results

These facilities match your main criteria but not every optional filter — including other countries in the same region.

HIPRA BIOTECH SERVICES | Aiguaviva
Spain

HIPRA BIOTECH SERVICES | Aiguaviva

HIPRA Biotech Services

End-to-end internal capabilities from cell line development to commercial manufacturing.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia)

COMPLIANCE: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

BSL (Biological Safety Level): 1, 2

USE: Human

BATCH SIZE: Large, Small, Medium

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

REGION: Europe

CATEGORY / PRODUCT: BIOLOGICS

Adare Pharma | EU
Italy

Adare Pharma | EU

Adare Pharma Solutions

Global CDMO offering turnkey product development through commercial manufacturing expertise, focused on oral dosage forms.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), EDE (UAE), TGA (Australia)

COMPLIANCE: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Halal Research Council, ECOVADIS, TGA (Australia GMP), TITCK (Turkish Health Authorities), UAE Ministry of Health & Prevention, French Service-Public (CIR), NMPA (China GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

USE: Human, Veterinary

BATCH SIZE: Large, Small, Medium

THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (J) Antiinfectives for systemic use, (V01) Allergens, (R) Respiratory system, (M) Musculoskeletal system, (C) Cardiovascular system, (A) Digestive tract and metabolism

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, PARTICLE ENGINEERING, SERVICES

REGION: Europe

CZ Vaccines | Large Scale Plant Portugal
Portugal

CZ Vaccines | Large Scale Plant Portugal

CZ Vaccines

Commercial Scale Facility

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU)

COMPLIANCE: ISO, EMA (EU GMP), World Health Organization (GMP / HACCP)

BSL (Biological Safety Level): 1, 2

USE: Human

BATCH SIZE: Large, Medium

THERAPEUTIC AREAS OF EXPERTISE (ATC): (J) Antiinfectives for systemic use, (R) Respiratory system, (G) Genito urinary system and sex hormones

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, BIOLOGICS

REGION: Europe

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+1 more facilities

Create free account

France has established itself as a prominent hub for Contract Development and Manufacturing Organizations (CDMOs) in the pharmaceutical industry. French CDMOs provide end-to-end services, from drug development to commercial production, supporting global pharmaceutical and biotech companies in bringing innovative therapies to market.

Why Choose CDMOs in France?

Offering French CDMOs are recognized for their state-of-the-art facilities, regulatory excellence, and flexible, cost-effective solutions. They offer a broad range of services, covering various dosage forms such as oral solids, injectables, and complex formulations like lyophilized and sustained-release products. With certifications from regulatory authorities such as EMA and FDA, CDMOs in France are well-equipped to manage projects across preclinical, clinical, and commercial phases.

Leveraging strategic positioning, French CDMOs benefit from excellent global market access, ensuring streamlined logistics and rapid distribution. By adopting innovative technologies, they provide solutions that address even the most complex pharmaceutical challenges.

Key Services Offered by Contract Manufacturers in France

Providing Drug Development: Expertise in formulation development, process optimization, and analytical testing to ensure product stability, efficacy, and scalability.

Ensuring Manufacturing: High-volume production for oral solids, liquids, semi-solids, injectables, and more, ensuring flexibility and superior output quality.

Delivering Regulatory Support: Comprehensive assistance with regulatory filings for EMA, FDA, and other international authorities to ensure full compliance and readiness for market entry.

Offering Packaging Solutions: CDMOs in France offer tailored primary and secondary packaging services, guaranteeing product protection and adherence to regulatory standards.

Advantages of Partnering with French CDMOs

Demonstrating Regulatory Expertise: French CDMOs have an in-depth understanding of European and international regulatory requirements, ensuring products meet the highest safety and efficacy standards.

Utilizing State-of-the-Art Facilities: Equipped with cutting-edge technologies, CDMOs in France specialize in aseptic processing and high-containment manufacturing to ensure quality and efficiency.

Capitalizing on Strategic Location: France’s central position within Europe ensures seamless logistics and rapid distribution to key markets worldwide.

Providing Cost-Effective Solutions: French CDMOs offer competitive pricing while maintaining superior quality, making them a smart choice for pharmaceutical partnerships.

Promoting Sustainability Commitment: Many CDMOs in France implement environmentally friendly practices, aligning with global sustainability initiatives for eco-conscious production.

CDMO Companies in France

Some of the top CDMO companies in France:

CDM Lavoisier: CDMO in France specialized in the manufacturing of glass ampoules, glass vials and plastic (BFS) ampoules. [See CDMO profile]

Cenexi: French CDMO specialized in the manufacture and filling of injectable and non-injectable sterile liquid products. [See CDMO profile]

Skyepharma: Fully integrated French CDMO, key player in drug development and oral technologies delivery. [See CDMO profile]

CARBOGEN AMCIS: Custom formulation development and GMP sterile manufacture of liquid and lyophilized drug products. [See CDMO profile]

AdhexPharma SAS: CDMO specialized in transdermal patches and oromucosal films. [See CDMO profile]

Adragos Pharma: Sterile liquids and suppositories manufacturing, handling >100 molecules with stability, narcotics, and analytical services. [See CDMO profile]

Unither Pharmaceuticals: Affordable healthcare solutions. [See CDMO profile]

Related Information

Leading CDMO Companies in Europe

Leading CDMO Companies in Germany

Leading CDMO Companies in Italy

Leading CDMO Companies in Spain

Let MAI CDMO Help You Find the Right French Partner

Choosing the right CDMO partner can be complex, but MAI CDMO simplifies the process. We connect you with pre-vetted CDMOs in France that meet your unique project needs. Our dedicated experts provide personalized support to align your goals with the strengths of French CDMOs, ensuring a successful transition from development to commercialization.

Whether you’re in the early stages of drug development or looking for a partner for full-scale production, MAI CDMO offers unmatched industry expertise and connections.

Contact us today to explore the best French CDMO companies and start your pharmaceutical journey with a trusted partner.